In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.
Cardiac biomarker
Cardioprotection
Cardiotoxic
Chemotherapy
Rodent model
Ventricular function
Journal
Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
22
12
2021
accepted:
04
03
2022
pubmed:
22
3
2022
medline:
3
11
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Modern therapeutic approaches have led to an improvement in the chances of surviving a diagnosis of cancer. However, this may come with side effects, with patients experiencing adverse cardiovascular events or exacerbation of underlying cardiovascular disease related to their cancer treatment. Rodent models of chemotherapy-induced cardiotoxicity are useful to define pathophysiological mechanisms of cardiac damage and to identify potential therapeutic targets. The key mechanisms involved in cardiotoxicity induced by specific different antineoplastic agents are summarized in this state-of-the-art review, as well as the rodent models of cardiotoxicity by different classes of anticancer drugs, along with the strategies tested for primary and secondary cardioprotection. Current approaches for early detection of cardiotoxicity in preclinical studies with a focus on the application of advanced imaging modalities and biomarker strategies are also discussed. Potential applications of cardiotoxicity modelling in rodents are illustrated in relation to the advancements of promising research topics of cardiotoxicity. Created with BioRender.com.
Identifiants
pubmed: 35312959
doi: 10.1007/s12265-022-10231-2
pii: 10.1007/s12265-022-10231-2
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1162Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., et al. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 15(10), 1063–1093. https://doi.org/10.1093/ehjci/jeu192
doi: 10.1093/ehjci/jeu192
pubmed: 25239940
pmcid: 4402366
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., De Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology, 23(SUPPL. 7). https://doi.org/10.1093/annonc/mds293
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., et al. (2016). Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation, 133(17), 1668–1687. https://doi.org/10.1161/CIRCULATIONAHA.115.017443
doi: 10.1161/CIRCULATIONAHA.115.017443
pubmed: 26984939
pmcid: 4856587
Asnani, A., Moslehi, J. J., Adhikari, B. B., Baik, A. H., Beyer, A. M., De Boer, R. A., et al. (2021). Preclinical models of cancer therapy-associated cardiovascular toxicity: A scientific statement from the American Heart Association. Circulation Research. https://doi.org/10.1161/RES.0000000000000473
doi: 10.1161/RES.0000000000000473
pubmed: 34591656
pmcid: 8423100
Latifi, Y., Moccetti, F., Wu, M., Xie, A., Packwood, W., Qi, Y., et al. (2019). Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood, 133(14). https://doi.org/10.1182/blood-2018-10-881557
Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 8(5). https://doi.org/10.1038/nm0502-459
Chintalgattu, V., Rees, M. L., Culver, J. C., Goel, A., Jiffar, T., Zhang, J., et al. (2013). Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Science Translational Medicine, 5(187). https://doi.org/10.1126/scitranslmed.3005066
Efentakis, P., Kremastiotis, G., Varela, A., Nikolaou, P. E., Papanagnou, E. D., Davos, C. H., et al. (2019). Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood, 133(7). https://doi.org/10.1182/blood-2018-06-858415
Herrmann, J., Wohlert, C., Saguner, A. M., Flores, A., Nesbitt, L. L., Chade, A., et al. (2013). Primary proteasome inhibition results in cardiac dysfunction. European Journal of Heart Failure, 15(6). https://doi.org/10.1093/eurjhf/hft034
Yang, B., & Papoian, T. (2018). Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future. Journal of Applied Toxicology. https://doi.org/10.1002/jat.3584
doi: 10.1002/jat.3584
pubmed: 30265375
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 291(5502). https://doi.org/10.1126/science.291.5502.319
Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N. A. A. S., Screever, E. M., Wescott, E. C., et al. (2021). A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discovery, 11(3), 614–625. https://doi.org/10.1158/2159-8290.CD-20-0856
doi: 10.1158/2159-8290.CD-20-0856
pubmed: 33257470
Gabriels, K., Hoving, S., Seemann, I., Visser, N. L., Gijbels, M. J., Pol, J. F., et al. (2012). Local heart irradiation of ApoE-/- mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis. Radiotherapy and Oncology, 105(3). https://doi.org/10.1016/j.radonc.2012.08.002
Schlaak, R. A., Frei, A., Schottstaedt, A. M., Tsaih, S. W., Fish, B. L., Harmann, L., et al. (2019). Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. American Journal of Physiology - Heart and Circulatory Physiology, 316(6). https://doi.org/10.1152/ajpheart.00482.2018
Iqubal, A., Sharma, S., Ansari, M. A., Najmi, A. K., Syed, M. A., Ali, J., et al. (2019). Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice. European Journal of Pharmacology, 863. https://doi.org/10.1016/j.ejphar.2019.172666
Krüse, J. J. C. M., Zurcher, C., Strootman, E. G., Bart, C. I., Schlagwein, N., Leer, J. W. H., & Wondergem, J. (2001). Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiotherapy and Oncology, 58(3). https://doi.org/10.1016/S0167-8140(00)00327-3
Iqubal, A., Iqubal, M. K., Sharma, S., Ansari, M. A., Najmi, A. K., Ali, S. M., et al. (2019). Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sciences. https://doi.org/10.1016/j.lfs.2018.12.018
doi: 10.1016/j.lfs.2018.12.018
pubmed: 31520598
Srivastava, S., Sithu, S. D., Vladykovskaya, E., Haberzettl, P., Hoetker, D. J., Siddiqui, M. A., et al. (2011). Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis, 215(2). https://doi.org/10.1016/j.atherosclerosis.2011.01.001
Zhang, K., Heidrich, F. M., DeGray, B., Boehmerle, W., & Ehrlich, B. E. (2010). Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R. Journal of Molecular and Cellular Cardiology, 49(5). https://doi.org/10.1016/j.yjmcc.2010.08.018
El-Awady, E. S. E., Moustafa, Y. M., Abo-Elmatty, D. M., & Radwan, A. (2011). Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. European Journal of Pharmacology, 650(1). https://doi.org/10.1016/j.ejphar.2010.09.085
Ma, H., Jones, K. R., Guo, R., Xu, P., Shen, Y., & Ren, J. (2010). Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clinical and Experimental Pharmacology and Physiology, 37(4). https://doi.org/10.1111/j.1440-1681.2009.05323.x
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12(8). https://doi.org/10.1038/nm1446
Lu, Z., Wu, C. Y. C., Jiang, Y. P., Ballou, L. M., Clausen, C., Cohen, I. S., & Lin, R. Z. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Science Translational Medicine, 4(131). https://doi.org/10.1126/scitranslmed.3003623
Gintant, G., Burridge, P., Gepstein, L., Harding, S., Herron, T., Hong, C., et al. (2019). Use of human induced pluripotent stem cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: A scientific statement from the American Heart Association. Circulation Research. https://doi.org/10.1161/RES.0000000000000291
doi: 10.1161/RES.0000000000000291
pubmed: 31533542
pmcid: 7398423
Ewer, M. S., & Lippman, S. M. (2005). Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2005.05.827
doi: 10.1200/JCO.2005.05.827
pubmed: 16258084
Murabito, A., Hirsch, E., & Ghigo, A. (2020). Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer? Frontiers in Cardiovascular Medicine, 7. https://doi.org/10.3389/fcvm.2020.00035
Cardinale, D., Fabiani, I., & Cipolla, C. (2020). Cardiotoxicity of anthracycline. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2020.00026
doi: 10.3389/fcvm.2020.00026
pubmed: 32258060
pmcid: 7093379
Polegato, B. F., Minicucci, M. F., Azevedo, P. S., Carvalho, R. F., Chiuso-Minicucci, F., Pereira, E. J., et al. (2015). Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats. Cellular Physiology and Biochemistry, 35(5), 1924–1933. https://doi.org/10.1159/000374001
doi: 10.1159/000374001
pubmed: 25871735
Ruan, Y., Dong, C., Patel, J., Duan, C., Wang, X., Wu, X., et al. (2015). SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways. Cellular Physiology and Biochemistry, 35(3), 1116–1124. https://doi.org/10.1159/000373937
doi: 10.1159/000373937
pubmed: 25766524
Wei, S. N., Zhao, W. J., Zeng, X. J., Kang, Y. M., Du, J., & Li, H. H. (2015). Microarray and co-expression network analysis of genes associated with acute doxorubicin cardiomyopathy in mice. Cardiovascular Toxicology, 15(4), 377–393. https://doi.org/10.1007/s12012-014-9306-7
doi: 10.1007/s12012-014-9306-7
pubmed: 25575753
De Carvalho, P. B., Gonçalves, A. D. F., Alegre, P. H. C., Azevedo, P. S., Roscani, M. G., Bergamasco, C. M., et al. (2016). Pamidronate attenuates oxidative stress and energetic metabolism changes but worsens functional outcomes in acute doxorubicin-induced cardiotoxicity in rats. Cellular Physiology and Biochemistry, 40(3–4), 431–442. https://doi.org/10.1159/000452558
doi: 10.1159/000452558
pubmed: 27889760
O’Connell, J. L., Romano, M. M. D., Campos Pulici, E. C., Carvalho, E. E. V., de Souza, F. R., Tanaka, D. M., et al. (2017). Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. Experimental and Toxicologic Pathology, 69(4), 213–219. https://doi.org/10.1016/j.etp.2017.01.004
doi: 10.1016/j.etp.2017.01.004
pubmed: 28153388
Richard, C., Lauzier, B., Delemasure, S., Talbot, S., Ghibu, S., Collin, B., et al. (2008). Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats. Journal of Cardiovascular Pharmacology, 52(3), 278–285. https://doi.org/10.1097/FJC.0b013e3181865f28
doi: 10.1097/FJC.0b013e3181865f28
pubmed: 18806609
Pecoraro, M., Del Pizzo, M., Marzocco, S., Sorrentino, R., Ciccarelli, M., Iaccarino, G., et al. (2016). Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicology and Applied Pharmacology, 293, 44–52. https://doi.org/10.1016/j.taap.2016.01.006
doi: 10.1016/j.taap.2016.01.006
pubmed: 26780402
Bi, L., Zhang, H., Han, R., Chen, W., & Zhao, N. (2020). Application of a combination of echocardiographic techniques in an experimental model of epirubicin-induced cardiotoxicity. International Journal of Cardiovascular Imaging, 36(5), 841–854. https://doi.org/10.1007/s10554-020-01777-w
doi: 10.1007/s10554-020-01777-w
pubmed: 32034566
Cappetta, D., Esposito, G., Coppini, R., Piegari, E., Russo, R., Ciuffreda, L. P., et al. (2017). Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. British Journal of Pharmacology, 174(21), 3696–3712. https://doi.org/10.1111/bph.13791
doi: 10.1111/bph.13791
pubmed: 28320043
pmcid: 5647186
Bertinchant, J. P., Polge, A., Juan, J. M., Oliva-Lauraire, M. C., Giuliani, I., Marty-Double, C., et al. (2003). Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clinica Chimica Acta, 329(1–2), 39–51. https://doi.org/10.1016/S0009-8981(03)00013-5
doi: 10.1016/S0009-8981(03)00013-5
Neilan, T. G., Jassal, D. S., Perez-Sanz, T. M., Raher, M. J., Pradhan, A. D., Buys, E. S., et al. (2006). Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. European Heart Journal, 27(15), 1868–1875. https://doi.org/10.1093/eurheartj/ehl013
doi: 10.1093/eurheartj/ehl013
pubmed: 16717080
Gabrielson, K., Bedja, D., Pin, S., Tsao, A., Gama, L., Yuan, B., & Muratore, N. (2007). Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Research, 67(4), 1436–1441. https://doi.org/10.1158/0008-5472.CAN-06-3721
doi: 10.1158/0008-5472.CAN-06-3721
pubmed: 17308081
Hayward, R., & Hydock, D. S. (2007). Doxorubicin cardiotoxicity in the rat: An in vivo characterization. Journal of the American Association for Laboratory Animal Science, 46(4), 20–32.
pubmed: 17645292
Xiang, P., Deng, H. Y., Li, K., Huang, G. Y., Chen, Y., Tu, L., et al. (2009). Dexrazoxane protects against doxorubicin-induced cardiomyopathy: Upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemotherapy and Pharmacology, 63(2), 343–349. https://doi.org/10.1007/s00280-008-0744-4
doi: 10.1007/s00280-008-0744-4
pubmed: 18379782
Hullin, R., Métrich, M., Sarre, A., Basquin, D., Maillard, M., Regamey, J., & Martin, D. (2018). Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovascular Research, 114(2), 272–281. https://doi.org/10.1093/cvr/cvx162
doi: 10.1093/cvr/cvx162
pubmed: 29016737
Sabatino, J., De Rosa, S., Tammè, L., Iaconetti, C., Sorrentino, S., Polimeni, A., et al. (2020). Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovascular diabetology, 19(1), 66. https://doi.org/10.1186/s12933-020-01040-5
doi: 10.1186/s12933-020-01040-5
pubmed: 32414364
pmcid: 7229599
Vermeulen, Z., Segers, V. F. M., & De Keulenaer, G. W. (2016). ErbB2 signaling at the crossing between heart failure and cancer. Basic Research in Cardiology. https://doi.org/10.1007/s00395-016-0576-z
doi: 10.1007/s00395-016-0576-z
pubmed: 27596216
pmcid: 5011481
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783–792. https://doi.org/10.1056/nejm200103153441101
doi: 10.1056/nejm200103153441101
pubmed: 11248153
Riccio, G., Coppola, C., Piscopo, G., Capasso, I., Maurea, C., Esposito, E., et al. (2016). Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Human Vaccines and Immunotherapeutics, 12(5), 1124–1131. https://doi.org/10.1080/21645515.2015.1125056
doi: 10.1080/21645515.2015.1125056
pubmed: 26836985
pmcid: 4963071
Voigtlaender, M., Schneider-Merck, T., & Trepel, M. (2018). Lapatinib. In Recent Results in Cancer Research, 211, 19–44. https://doi.org/10.1007/978-3-319-91442-8_2
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., De Azambuja, E., Aura, C., et al. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. In The Lancet, 379. https://doi.org/10.1016/S0140-6736(11)61847-3
Kabel, A. M., & Elkhoely, A. A. (2017). Targeting proinflammatory cytokines, oxidative stress, TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomedicine and Pharmacotherapy, 93, 17–26. https://doi.org/10.1016/j.biopha.2017.06.033
doi: 10.1016/j.biopha.2017.06.033
pubmed: 28622591
Jassal, D. S., Han, S. Y., Hans, C., Sharma, A., Fang, T., Ahmadie, R., et al. (2009). Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. Journal of the American Society of Echocardiography, 22(4), 418–424. https://doi.org/10.1016/j.echo.2009.01.016
doi: 10.1016/j.echo.2009.01.016
pubmed: 19269133
Riccio, G., Esposito, G., Leoncini, E., Contu, R., Condorelli, G., Chiariello, M., et al. (2009). Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. The FASEB Journal, 23(9), 3171–3178. https://doi.org/10.1096/fj.09-131383
doi: 10.1096/fj.09-131383
pubmed: 19417081
Fedele, C., Riccio, G., Coppola, C., Barbieri, A., Monti, M. G., Arra, C., et al. (2012). Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Research and Treatment, 133(2), 511–521. https://doi.org/10.1007/s10549-011-1783-9
doi: 10.1007/s10549-011-1783-9
pubmed: 21947749
Coppola, C., Riccio, G., Barbieri, A., Monti, M. G., Piscopo, G., Rea, D., et al. (2016). Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: Contribution of the new tool 2D-speckle tracking. OncoTargets and Therapy, 9, 6785–6794. https://doi.org/10.2147/OTT.S106528
doi: 10.2147/OTT.S106528
pubmed: 27843329
pmcid: 5098586
ElZarrad, M. K., Mukhopadhyay, P., Mohan, N., Hao, E., Dokmanovic, M., Hirsch, D. S., et al. (2013). Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS ONE, 8(11). https://doi.org/10.1371/journal.pone.0079543
Akolkar, G., Bhullar, N., Bews, H., Shaikh, B., Premecz, S., Bordun, K. A., et al. (2015). The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovascular Ultrasound, 13(1). https://doi.org/10.1186/s12947-015-0011-x
Milano, G., Raucci, A., Scopece, A., Daniele, R., Guerrini, U., Sironi, L., et al. (2014). Doxorubicin and trastuzumab regimen induces biventricular failure in mice. Journal of the American Society of Echocardiography, 27(5), 568–579. https://doi.org/10.1016/j.echo.2014.01.014
doi: 10.1016/j.echo.2014.01.014
pubmed: 24534652
Walker, J. R., Sharma, A., Lytwyn, M., Bohonis, S., Thliveris, J., Singal, P. K., & Jassal, D. S. (2011). The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. Journal of the American Society of Echocardiography, 24(6), 699–705. https://doi.org/10.1016/j.echo.2011.01.018
doi: 10.1016/j.echo.2011.01.018
pubmed: 21353471
Zeglinski, M., Ludke, A., Jassal, D. S., & Singal, P. K. (2011). Trastuzumab-induced cardiac dysfunction: a “dual-hit.” Experimental and Clinical Cardiology, 16(3), 70–74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209542/
Hsu, W. T., Huang, C. Y., Yen, C. Y. T., Cheng, A. L., & Hsieh, P. C. H. (2018). The HER2 inhibitor lapatinib potentiates doxorubicininduced cardiotoxicity through iNOS signaling. Theranostics, 8(12), 3176–3188. https://doi.org/10.7150/thno.23207
doi: 10.7150/thno.23207
pubmed: 29930721
pmcid: 6010982
Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology. https://doi.org/10.1038/nrcardio.2015.65
doi: 10.1038/nrcardio.2015.65
pubmed: 26416005
Bellinger, A. M., Arteaga, C. L., Force, T., Humphreys, B. D., Demetri, G. D., Druker, B. J., & Moslehi, J. J. (2015). Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.115.010484
doi: 10.1161/CIRCULATIONAHA.115.010484
pubmed: 26644247
pmcid: 4863699
Qi, W. X., Shen, Z., Tang, L. N., & Yao, Y. (2014). Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: A systematic review and meta-analysis of 36 clinical trials. British Journal of Clinical Pharmacology, 78(4), 748–762. https://doi.org/10.1111/bcp.12387
doi: 10.1111/bcp.12387
pubmed: 24661224
pmcid: 4239969
Abdel-Qadir, H., Ethier, J. L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2017). Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2016.12.002
doi: 10.1016/j.ctrv.2016.12.002
pubmed: 28104567
Bronte, E., Bronte, G., Novo, G., Rinaldi, G., Bronte, F., Passiglia, F., & Russo, A. (2018). Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2018.06.017
doi: 10.1016/j.pharmthera.2018.06.017
pubmed: 29964124
Douxfils, J., Haguet, H., Mullier, F., Chatelain, C., Graux, C., & Dogné, J. M. (2016). Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2015.5932
doi: 10.1001/jamaoncol.2015.5932
pubmed: 27281625
Curwen, J. O., Musgrove, H. L., Kendrew, J., Richmond, G. H. P., Ogilvie, D. J., & Wedge, S. R. (2008). Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clinical Cancer Research, 14(10), 3124–3131. https://doi.org/10.1158/1078-0432.CCR-07-4783
doi: 10.1158/1078-0432.CCR-07-4783
pubmed: 18483380
Kappers, M. H. W., Van Esch, J. H. M., Sluiter, W., Sleijfer, S., Danser, A. H. J., & Van Den Meiracker, A. H. (2010). Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension, 56(4), 675–681. https://doi.org/10.1161/HYPERTENSIONAHA.109.149690
doi: 10.1161/HYPERTENSIONAHA.109.149690
pubmed: 20733093
Bordun, K. A., Premecz, S., DaSilva, M., Mandal, S., Goyal, V., Glavinovic, T., et al. (2015). The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 309(4), H692–H701. https://doi.org/10.1152/ajpheart.00172.2015
doi: 10.1152/ajpheart.00172.2015
pubmed: 26092985
Harvey, P. A., & Leinwand, L. A. (2015). Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism. Cardiovascular Research, 107(1), 66–77. https://doi.org/10.1093/cvr/cvv152
doi: 10.1093/cvr/cvv152
pubmed: 26009590
pmcid: 4560048
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 370(9604), 2011–2019. https://doi.org/10.1016/S0140-6736(07)61865-0
doi: 10.1016/S0140-6736(07)61865-0
pubmed: 18083403
pmcid: 2643085
Jensen, B. C., Parry, T. L., Huang, W., Beak, J. Y., Ilaiwy, A., Bain, J. R., et al. (2017). Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. British Journal of Pharmacology, 174(24), 4797–4811. https://doi.org/10.1111/bph.14062
doi: 10.1111/bph.14062
pubmed: 28977680
pmcid: 5727336
Stuhlmiller, T. J., Zawistowski, J. S., Chen, X., Sciaky, N., Angus, S. P., Hicks, S. T., et al. (2017). Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. Journal of the American Heart Association, 6(10). https://doi.org/10.1161/JAHA.117.006635
Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. American Journal of Clinical Oncology: Cancer Clinical Trials. https://doi.org/10.1097/COC.0000000000000239
doi: 10.1097/COC.0000000000000239
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018). Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Frontiers in Oncology. https://doi.org/10.3389/fonc.2018.00086
doi: 10.3389/fonc.2018.00086
pubmed: 29644214
pmcid: 5883082
Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science. https://doi.org/10.1126/science.aar4060
doi: 10.1126/science.aar4060
pubmed: 30523081
pmcid: 6718162
Michel, L., Rassaf, T., & Totzeck, M. (2019). Cardiotoxicity from immune checkpoint inhibitors. IJC Heart and Vasculature. https://doi.org/10.1016/j.ijcha.2019.100420
doi: 10.1016/j.ijcha.2019.100420
pubmed: 31517036
pmcid: 6736791
Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., et al. (2017). Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.117.030571
doi: 10.1161/CIRCULATIONAHA.117.030571
pubmed: 29158217
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3(5). https://doi.org/10.1016/1074-7613(95)90125-6
Wang, J., Okazaki, I. M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., et al. (2010). PD-1 deficiency results in the development of fatal myocarditis in MRL mice. International Immunology, 22(6). https://doi.org/10.1093/intimm/dxq026
Grabie, N., Gotsman, I., DaCosta, R., Pang, H., Stavrakis, G., Butte, M. J., et al. (2007). Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell-mediated injury in the heart. Circulation, 116(18). https://doi.org/10.1161/CIRCULATIONAHA.107.709360
Park, K. C., Gaze, D. C., Collinson, P. O., & Marber, M. S. (2017). Cardiac troponins: From myocardial infarction to chronic disease. Cardiovascular Research. https://doi.org/10.1093/cvr/cvx183
doi: 10.1093/cvr/cvx183
pubmed: 29016754
pmcid: 5852618
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., et al. (2004). Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 109(22), 2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC
doi: 10.1161/01.CIR.0000130926.51766.CC
pubmed: 15148277
Cardinale, D., Salvatici, M., & Sandri, M. T. (2011). Role of biomarkers in cardioncology. Clinical Chemistry and Laboratory Medicine. https://doi.org/10.1515/CCLM.2011.692
doi: 10.1515/CCLM.2011.692
pubmed: 21892906
Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., Yu, Z. X., et al. (1998). Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Research, 58(2), 195–197.
pubmed: 9443390
Atas, E., Kismet, E., Kesik, V., Karaoglu, B., Aydemir, G., Korkmazer, N., et al. (2015). Cardiac troponin-I, brain natriuretic peptide and endothelin-1 levels in a rat model of doxorubicin-induced cardiac injury. Journal of Cancer Research and Therapeutics, 11(4), 882–886. https://doi.org/10.4103/0973-1482.144636
doi: 10.4103/0973-1482.144636
pubmed: 26881535
Reagan, W. J., York, M., Berridge, B., Schultze, E., Walker, D., & Pettit, S. (2013). Comparison of Cardiac Troponin I and T, Including the evaluation of an ultrasensitive assay, as indicators of doxorubicin-induced cardiotoxicity. Toxicologic Pathology, 41(8), 1146–1158. https://doi.org/10.1177/0192623313482056
doi: 10.1177/0192623313482056
pubmed: 23531791
Ibrahim, N. E., & Januzzi, J. L. (2018). Established and emerging roles of biomarkers in heart failure. Circulation Research. https://doi.org/10.1161/CIRCRESAHA.118.312706
doi: 10.1161/CIRCRESAHA.118.312706
pubmed: 30566047
pmcid: 6390975
Putt, M., Hahn, V. S., Januzzi, J. L., Sawaya, H., Sebag, I. A., Plana, J. C., et al. (2015). Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clinical Chemistry, 61(9), 1164–1172. https://doi.org/10.1373/clinchem.2015.241232
doi: 10.1373/clinchem.2015.241232
pubmed: 26220066
pmcid: 4667170
Demissei, B. G., Hubbard, R. A., Zhang, L., Smith, A. M., Sheline, K., McDonald, C., et al. (2020). Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. Journal of the American Heart Association, 9(2). https://doi.org/10.1161/JAHA.119.014708
Wu, R., Wang, H. L., Yu, H. L., Cui, X. H., Xu, M. T., Xu, X., & Gao, J. P. (2016). Doxorubicin toxicity changes myocardial energy metabolism in rats. Chemico-Biological Interactions, 244. https://doi.org/10.1016/j.cbi.2015.12.010
Colpaert, R. M. W., & Calore, M. (2019). MicroRNAs in Cardiac Diseases. Cells, 8(7), 737. https://doi.org/10.3390/cells8070737
doi: 10.3390/cells8070737
pmcid: 6678080
Desai, V. G., Kwekel, J. C., Vijay, V., Moland, C. L., Herman, E. H., Lee, T., et al. (2014). Early biomarkers of doxorubicin-induced heart injury in a mouse model. Toxicology and Applied Pharmacology, 281(2), 221–229. https://doi.org/10.1016/j.taap.2014.10.006
doi: 10.1016/j.taap.2014.10.006
pubmed: 25448438
Duan, Y., Zhou, B., Su, H., Liu, Y., & Du, C. (2013). MiR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Experimental Cell Research, 319(3), 173–184. https://doi.org/10.1016/j.yexcr.2012.11.015
doi: 10.1016/j.yexcr.2012.11.015
pubmed: 23211718
Vacchi-Suzzi, C., Bauer, Y., Berridge, B. R., Bongiovanni, S., Gerrish, K., Hamadeh, H. K., et al. (2012). Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS ONE, 7(7). https://doi.org/10.1371/journal.pone.0040395
Gioffré, S., Ricci, V., Vavassori, C., Ruggeri, C., Chiesa, M., Alfieri, I., et al. (2019). Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity. Biomedicine and Pharmacotherapy, 110, 1–8. https://doi.org/10.1016/j.biopha.2018.11.042
doi: 10.1016/j.biopha.2018.11.042
pubmed: 30453253
Fabiani, I., Pugliese, N. R., Santini, V., Conte, L., & Di Bello, V. (2016). Speckle-tracking imaging, principles and clinical applications: a review for clinical cardiologists. In Echocardiography in Heart Failure and Cardiac Electrophysiology. https://doi.org/10.5772/64261
Farhad, H., Staziaki, P. V., Addison, D., Coelho-Filho, O. R., Shah, R. V., Mitchell, R. N., et al. (2016). Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circulation: Cardiovascular Imaging, 9(12). https://doi.org/10.1161/CIRCIMAGING.115.003584
Lightfoot, J. C., D’Agostino, R. B., Hamilton, C. A., Jordan, J., Torti, F. M., Kock, N. D., et al. (2010). Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circulation: Cardiovascular Imaging, 3(5), 550–558. https://doi.org/10.1161/CIRCIMAGING.109.918540
doi: 10.1161/CIRCIMAGING.109.918540
Herman, E., Ardalan, B., Bier, C., Waravdekar, V., & Krop, S. (1979). Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treatment Reports, 63(1), 89–92.
pubmed: 421236
Herman, E. H., & Ferrans, V. J. (1998). Preclinical animal models of cardiac protection from anthracycline- induced cardiotoxicity. Seminars in Oncology. https://doi.org/10.1093/cvr/cvx246
Lódi, M., Priksz, D., Fülöp, G. Á., Bódi, B., Gyöngyösi, A., Nagy, L., et al. (2019). Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 17(1). https://doi.org/10.1186/s12967-019-1978-0
Lódi, M., Bánhegyi, V., Bódi, B., Gyöngyösi, A., Kovács, Á., Árokszállási, A., et al. (2020). Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 18(1). https://doi.org/10.1186/s12967-020-02564-w
Cadeddu Dessalvi, C., Deidda, M., Noto, A., Madeddu, C., Cugusi, L., Santoro, C., et al. (2021). Antioxidant approach as a cardioprotective strategy in chemotherapy-induced cardiotoxicity. Antioxidants and Redox Signaling. https://doi.org/10.1089/ars.2020.8055
doi: 10.1089/ars.2020.8055
pubmed: 32151144
Sacco, G., Bigioni, M., Lopez, G., Evangelista, S., Manzini, S., & Maggi, C. A. (2009). ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. Vascular Pharmacology, 50(5–6), 166–170. https://doi.org/10.1016/j.vph.2009.01.001
doi: 10.1016/j.vph.2009.01.001
pubmed: 19344651
Toko, H., Oka, T., Zou, Y., Sakamoto, M., Mizukami, M., Sano, M., et al. (2002). Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertension Research, 25(4), 597–603. https://doi.org/10.1291/hypres.25.597
doi: 10.1291/hypres.25.597
pubmed: 12358147
Sobczuk, P., Czerwińska, M., Kleibert, M., & Cudnoch-Jędrzejewska, A. (2020). Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications. Heart Failure Reviews. https://doi.org/10.1007/s10741-020-09977-1
doi: 10.1007/s10741-020-09977-1
pmcid: 8739307
Soga, M., Kamal, F. A., Watanabe, K., Ma, M., Palaniyandi, S., Prakash, P., et al. (2006). Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. International Journal of Cardiology, 110(3), 378–385. https://doi.org/10.1016/j.ijcard.2005.08.061
doi: 10.1016/j.ijcard.2005.08.061
pubmed: 16324756
Yamagishi, S., & Takeuchi, M. (2005). Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing property. Medical Hypotheses, 64(3), 476–478. https://doi.org/10.1016/j.mehy.2004.09.015
doi: 10.1016/j.mehy.2004.09.015
pubmed: 15617852
Iqbal, M., Dubey, K., Anwer, T., Ashish, A., & Pillai, K. K. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports, 60(3), 382–390.
pubmed: 18622063
Chang, S. A., Lim, B. K., Lee, Y. J., Hong, M. K., Choi, J. O., & Jeon, E. S. (2015). A novel angiotensin type I receptor antagonist, fimasartan, prevents doxorubicin-induced cardiotoxicity in rats. Journal of Korean Medical Science, 30(5), 559–568. https://doi.org/10.3346/jkms.2015.30.5.559
doi: 10.3346/jkms.2015.30.5.559
pubmed: 25931786
pmcid: 4414639
Boutagy, N. E., Feher, A., Pfau, D., Liu, Z., Guerrera, N. M., Freeburg, L. A., et al. (2020). Dual angiotensin receptor-neprilysin inhibition with sacubitril/valsartan attenuates systolic dysfunction in experimental doxorubicin-induced cardiotoxicity. JACC: CardioOncology, 2(5), 774–787. https://doi.org/10.1016/j.jaccao.2020.09.007
doi: 10.1016/j.jaccao.2020.09.007
pubmed: 33437965
pmcid: 7799406
Rashikh, A., Najmi, A. K., Akhtar, M., Mahmood, D., Pillai, K. K., & Ahmad, S. J. (2011). Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Human and Experimental Toxicology, 30(2), 102–109. https://doi.org/10.1177/0960327110369819
doi: 10.1177/0960327110369819
pubmed: 20418268
Rashikh, A., Ahmad, S. J., Pillai, K. K., Kohli, K., & Najmi, A. K. (2012). Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy. Biomedicine and Pharmacotherapy, 66(2), 138–143. https://doi.org/10.1016/j.biopha.2011.11.020
doi: 10.1016/j.biopha.2011.11.020
pubmed: 22386366
Liu, G., Liu, Y., Wang, R., Hou, T., Chen, C., Zheng, S., & Dong, Z. (2016). Spironolactone attenuates doxorubicin-induced cardiotoxicity in rats. Cardiovascular Therapeutics, 34(4), 216–224. https://doi.org/10.1111/1755-5922.12189
doi: 10.1111/1755-5922.12189
pubmed: 27097055
Lother, A., Bergemann, S., Kowalski, J., Huck, M., Gilsbach, R., Bode, C., & Hein, L. (2018). Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Cardiovascular Research, 114(2), 282–290. https://doi.org/10.1093/cvr/cvx078
doi: 10.1093/cvr/cvx078
pubmed: 28430882
Fu, M., Matoba, M., Liang, Q. M., Sjögren, K. G., & Hjalmarson, Å. (1994). Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin. International Journal of Cardiology, 44(1), 9–18. https://doi.org/10.1016/0167-5273(94)90061-2
doi: 10.1016/0167-5273(94)90061-2
pubmed: 8021056
Bernstein, D., Fajardo, G., Zhao, M., Urashima, T., Powers, J., Berry, G., & Kobilka, B. K. (2005). Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. American Journal of Physiology - Heart and Circulatory Physiology, 289(6 58–6). https://doi.org/10.1152/ajpheart.00005.2005
Fajardo, G., Zhao, M., Powers, J., & Bernstein, D. (2006). Differential cardiotoxic/cardioprotective effects of β-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. Journal of Molecular and Cellular Cardiology, 40(3), 375–383. https://doi.org/10.1016/j.yjmcc.2005.12.004
doi: 10.1016/j.yjmcc.2005.12.004
pubmed: 16458323
pmcid: 3140223
Khan, M. U., Zhao, W., Zhao, T., Al Darazi, F., Ahokas, R. A., Sun, Y., et al. (2013). Nebivolol: A multifaceted antioxidant and cardioprotectant in hypertensive heart disease. Journal of Cardiovascular Pharmacology, 62(5), 445–451. https://doi.org/10.1097/FJC.0b013e3182a0b5ff
doi: 10.1097/FJC.0b013e3182a0b5ff
pubmed: 23921314
Feleszko, W., Młynarczuk, I., Bałkowiec-Iskra, E. Z., Czajka, A., Świtaj, T., Stokłosa, T., et al. (2000). Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clinical Cancer Research, 6(5), 2044–2052.
pubmed: 10815931
Huelsenbeck, J., Henninger, C., Schad, A., Lackner, K. J., Kaina, B., & Fritz, G. (2011). Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death and Disease, 2(8). https://doi.org/10.1038/cddis.2011.65
Sharma, H., Pathan, R. A., Kumar, V., Javed, S., & Bhandari, U. (2011). Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. International Journal of Cardiology, 150(2), 193–200. https://doi.org/10.1016/j.ijcard.2010.04.008
doi: 10.1016/j.ijcard.2010.04.008
pubmed: 20452068
Kim, Y. H., Park, S. M., Kim, M., Kim, S. H., Lim, S. Y., Ahn, J. C., et al. (2012). Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats. Toxicology Mechanisms and Methods, 22(6), 488–498. https://doi.org/10.3109/15376516.2012.678406
doi: 10.3109/15376516.2012.678406
pubmed: 22455613
Henninger, C., & Fritz, G. (2017). Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death and Disease. https://doi.org/10.1038/cddis.2016.418
doi: 10.1038/cddis.2016.418
pubmed: 28796249
pmcid: 5596560
Saleh, D. O., Mansour, D. F., & Mostafa, R. E. (2020). Rosuvastatin and simvastatin attenuate cisplatin-induced cardiotoxicity via disruption of endoplasmic reticulum stress-mediated apoptotic death in rats: Targeting ER-Chaperone GRP78 and Calpain-1 pathways. Toxicology Reports, 7, 1178–1186. https://doi.org/10.1016/j.toxrep.2020.08.026
doi: 10.1016/j.toxrep.2020.08.026
pubmed: 32995293
pmcid: 7501485
Finet, J. E., & Wilson Tang, W. H. (2018). Protecting the heart in cancer therapy [version 1; peer review: 2 approved]. F1000Research. https://doi.org/10.12688/F1000RESEARCH.15190.1
Ajzashokouhi, A. H., Bostan, H. B., Jomezadeh, V., Hayes, A. W., & Karimi, G. (2020). A review on the cardioprotective mechanisms of metformin against doxorubicin. Human and Experimental Toxicology. https://doi.org/10.1177/0960327119888277
doi: 10.1177/0960327119888277
pubmed: 31735071
AlAsmari, A. F., Ali, N., AlAsmari, F., AlAnazi, W. A., AlShammari, M. A., Al-Harbi, N. O., et al. (2020). Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways. Saudi Pharmaceutical Journal, 28(4), 509–518. https://doi.org/10.1016/j.jsps.2020.03.002
doi: 10.1016/j.jsps.2020.03.002
pubmed: 32273812
pmcid: 7132601
Ibrahim, M. A., Bakhaat, G. A., Tammam, H. G., Mohamed, R. M., & El-Naggar, S. A. (2019). Cardioprotective effect of green tea extract and vitamin E on Cisplatin-induced cardiotoxicity in mice: Toxicological, histological and immunohistochemical studies. Biomedicine and Pharmacotherapy, 113. https://doi.org/10.1016/j.biopha.2019.108731
Ayza, M. A., Zewdie, K. A., Tesfaye, B. A., Wondafrash, D. Z., & Berhe, A. H. (2020). The role of antioxidants in ameliorating cyclophosphamide-induced cardiotoxicity. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2020/4965171
doi: 10.1155/2020/4965171
pubmed: 32454939
pmcid: 7238386
Jay, S. M., Murthy, A. C., Hawkins, J. F., Wortzel, J. R., Steinhauser, M. L., Alvarez, L. M., et al. (2013). An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation, 128(2), 152–161. https://doi.org/10.1161/CIRCULATIONAHA.113.002203
doi: 10.1161/CIRCULATIONAHA.113.002203
pubmed: 23757312
pmcid: 3753575
Neilan, T. G., Jassal, D. S., Scully, M. F., Chen, G., Deflandre, C., McAllister, H., et al. (2006). Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. European Heart Journal, 27(10), 1251–1256. https://doi.org/10.1093/eurheartj/ehl003
doi: 10.1093/eurheartj/ehl003
pubmed: 16624831
Yang, Y., Li, N., Chen, T., Zhang, C., Liu, L., Qi, Y., & Bu, P. (2019). Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway. Pharmaceutical Biology, 57(1), 625–631. https://doi.org/10.1080/13880209.2019.1657905
doi: 10.1080/13880209.2019.1657905
pubmed: 31545912
pmcid: 6764339